Knockdown (KD) or inhibition of LSD1 reduces the proliferative capacity of cancer cells in different tumor models16,17 and numerous LSD1 inhibitors currently undergo clinical assessment for cancer therapy, particularly for small cell lung cancer (SCLC) and acute myeloid leukemia (AML)18. The gene discussed is KDM1A; the disease is cancer.